Artizan Biosciences is at the frontier of microbiome precision medicine, targeting, and blocking intestinal microbial-driven inflammation that are the root cause of many serious diseases.
Broad Approach
Using a novel small molecule approach, Artizan modulates intestinal dysbiosis by inhibiting specific, disease-associated microbial virulence factors in the intestinal tract.
Discovery Platform
Artizan’s proprietary drug discovery engine identifies and characterizes microbial drivers of disease within precise patient subsets in high-value areas including gastrointestinal, metabolic, autoimmune, and neurodegenerative diseases.
News
-
January 18, 2022
Artizan Biosciences Selects Lead Product Candidate for Inflammatory Bowel Disease Therapeutic Development Program
Artizan Biosciences, Inc., a precision medicine biotechnology company, today announced the selection of its lead product candidate, ARZC-001, for the treatment of inflammatory bowel disease (“IBD”). (more…)
-
November 18, 2021
Artizan Biosciences and Biohaven Therapeutics Announce Therapeutic Development Program in Parkinson’s Disease
Biohaven to leverage Artizan’s biobanking expertise and proprietary drug discovery engine to create Parkinson’s disease drug development program. (more…)
Artizan’s world-class biobanking program collects proprietary samples and clinical data from patients and healthy controls. These samples enable critical research into disease mechanisms and aid the development of potential treatments.